| Key TakeawaysSemaglutide produces greater weight loss than dulaglutide at comparable doses, with head-to-head trial data confirming the difference.Both are once-weekly GLP-1 receptor agonists with proven cardiovascular benefits, but their molecular structure, dosing range, and approved indications differ significantly.In India, semaglutide is now available as multiple DCGI-approved generics following patent expiry in March 2026, while dulaglutide (Trulicity) remains available by prescription through authorised distributors. |
If you or someone you know is navigating a choice between these two GLP-1 medications, you are asking exactly the right question.
This guide covers how each drug works, what the clinical trials actually show about weight loss, how their side effect profiles compare, and what their current availability looks like in India.
1. What Are Semaglutide and Dulaglutide, and How Do They Work?
Both semaglutide and dulaglutide belong to a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
They are injected once weekly and work by mimicking a naturally occurring hormone called GLP-1, which the small intestine releases after you eat.
When GLP-1 receptors are activated, several things happen at once. The pancreas releases more insulin in response to rising blood sugar. Glucagon secretion from the liver is suppressed, which would otherwise raise blood sugar further.
Gastric emptying slows down, meaning food moves out of the stomach more gradually. And in the brain, appetite signals are dampened, helping reduce how much you want to eat.
The result is lower blood sugar, reduced appetite, and, over time, meaningful weight loss.
Despite sharing this mechanism, semaglutide and dulaglutide are structurally distinct molecules, and those differences matter clinically.
How the molecular structures differ
Semaglutide (developed by Novo Nordisk) shares 94% structural homology with native human GLP-1. Its extended half-life of approximately 165 hours (roughly one week) is achieved through a C18 fatty acid side chain that binds tightly to albumin in the bloodstream, protecting the molecule from enzymatic degradation and renal clearance.
This tight albumin binding is also what gives semaglutide its stronger receptor engagement compared to earlier GLP-1 analogues.
Dulaglutide (developed by Eli Lilly) uses a different engineering approach. It consists of two modified GLP-1 molecules covalently fused to an immunoglobulin G4 (IgG4) Fc fragment, producing a large molecule of approximately 63 kilodaltons.
The molecule’s large size slows renal clearance and gives dulaglutide a half-life of approximately 4.5 to 5 days, allowing once-weekly administration.
The engineering difference matters because semaglutide’s albumin-binding strategy appears to produce stronger GLP-1 receptor activation, which translates to greater metabolic effects at clinically comparable doses.
Pharmacology at a Glance
| Feature | Semaglutide | Dulaglutide |
|---|---|---|
| Developed by | Novo Nordisk | Eli Lilly |
| Homology to native GLP-1 | 94% | 90% |
| Molecular strategy | C18 fatty acid + albumin binding | IgG4 Fc fusion protein |
| Half-life | ~165 hours (~7 days) | ~108 hours (~4.5 days) |
| Dosing frequency | Once weekly (subcutaneous) | Once weekly (subcutaneous) |
| Oral formulation available? | Yes (Rybelsus) | No |
| FDA approved for weight loss? | Yes (Wegovy, 2.4 mg) | No (diabetes only) |
| Brand names (India) | Ozempic, Wegovy + 40+ generics | Trulicity |
2. How Are They Dosed? Understanding the Titration Schedule
Both medications are started at a low dose and gradually increased over several weeks. This approach, called dose escalation or titration, allows the body to adjust and helps reduce gastrointestinal side effects such as nausea and vomiting.
With semaglutide, the standard titration for the diabetes indication (Ozempic) begins at 0.25 mg once weekly for four weeks, then increases to 0.5 mg. Based on clinical need and tolerability, the dose may be further increased to 1.0 mg.
For the dedicated weight management formulation (Wegovy), the target dose is 2.4 mg once weekly, reached over approximately 16 weeks of stepwise increases.
With dulaglutide, the starting dose is 0.75 mg once weekly. For individuals who need additional glycaemic control, the dose can be increased to 1.5 mg, 3.0 mg, or 4.5 mg.
The standard clinical doses used in head-to-head trial comparisons with semaglutide have been 0.75 mg and 1.5 mg.
Approved Dosing Ranges
| Dose Stage | Semaglutide (Ozempic) | Semaglutide (Wegovy) | Dulaglutide (Trulicity) |
|---|---|---|---|
| Starting dose | 0.25 mg/week | 0.25 mg/week | 0.75 mg/week |
| Intermediate dose | 0.5 mg/week | 0.5 mg/week | 1.5 mg/week |
| Standard/target dose | 1.0 mg/week | 2.4 mg/week | 1.5 mg/week |
| Maximum approved dose | 2.0 mg/week | 2.4 mg/week | 4.5 mg/week |
| Indication | Type 2 diabetes | Weight management | Type 2 diabetes |
3. What Does the Evidence Say About Weight Loss?
This is the question most people are actually asking. The most important piece of clinical evidence comes from the SUSTAIN 7 trial, the only large-scale, head-to-head comparison of semaglutide and dulaglutide conducted to date.
The SUSTAIN 7 trial: a direct comparison
Published in The Lancet Diabetes and Endocrinology in 2018, SUSTAIN 7 was a phase 3b, open-label, randomised controlled trial involving 1,199 adults with type 2 diabetes across 194 sites in 16 countries.
Participants were assigned to one of four groups: semaglutide 0.5 mg, dulaglutide 0.75 mg, semaglutide 1.0 mg, or dulaglutide 1.5 mg, all as add-on therapy to metformin over 40 weeks.
At week 40, the results were clear:
- Semaglutide 0.5 mg reduced body weight by 4.6 kg vs. 2.3 kg with dulaglutide 0.75 mg (p < 0.0001).
- Semaglutide 1.0 mg reduced body weight by 6.5 kg vs. 3.0 kg with dulaglutide 1.5 mg (p < 0.0001).
- HbA1c reduction with semaglutide 1.0 mg was 1.8 percentage points vs. 1.4 percentage points with dulaglutide 1.5 mg.
The weight loss advantage with semaglutide was consistent regardless of baseline body mass index, suggesting that the difference is driven by the drug’s pharmacology rather than by patient characteristics.
Semaglutide at the 2.4 mg weight management dose
The STEP 1 trial, published in The New England Journal of Medicine in 2021, tested semaglutide specifically at the higher 2.4 mg once-weekly dose that is approved for chronic weight management (Wegovy).
Among 1,961 adults overweight or obese without diabetes, semaglutide plus lifestyle intervention produced a mean body weight reduction of 14.9% at 68 weeks, compared to 2.4% with placebo.
An estimated 86% of participants on semaglutide achieved at least 5% weight loss.
Dulaglutide does not have an approved weight management indication and has not been tested at comparably high doses in obesity trials. Its weight loss data comes primarily from type 2 diabetes trials.
Head-to-Head Weight Loss Outcomes (SUSTAIN 7, 40 weeks)
| Drug and Dose | Mean Body Weight Reduction | HbA1c Reduction | Achieving HbA1c <7.0% |
|---|---|---|---|
| Semaglutide 0.5 mg | 4.6 kg | 1.5% | 56% |
| Dulaglutide 0.75 mg | 2.3 kg | 1.1% | 38% |
| Semaglutide 1.0 mg | 6.5 kg | 1.8% | 67% |
| Dulaglutide 1.5 mg | 3.0 kg | 1.4% | 57% |
Source: Pratley RE et al., Lancet Diabetes Endocrinol, 2018.
4. How Do Their Cardiovascular Benefits Compare?
Beyond blood sugar and weight, both medications have been evaluated in large cardiovascular outcomes trials, which is an important consideration for people with type 2 diabetes who are at elevated cardiac risk.
Semaglutide was studied in the SUSTAIN-6 trial, which demonstrated a statistically significant 26% reduction in major adverse cardiovascular events (MACE) compared to placebo, in adults with type 2 diabetes and high cardiovascular risk.
Dulaglutide was evaluated in the REWIND trial, published in The Lancet in 2019. Across 9,901 participants followed for a median of 5.4 years, dulaglutide reduced the risk of major cardiovascular events by 12% compared to placebo (hazard ratio 0.88; 95% CI 0.79 to 0.99; p = 0.026).
Notably, the REWIND trial included a broader population than most other GLP-1 cardiovascular trials, with only 31.5% of participants having a prior cardiovascular event, making the findings relevant to a wider range of patients.
Both drugs carry FDA and EMA approvals for cardiovascular risk reduction in adults with type 2 diabetes.
Neither has been shown to be definitively superior to the other in a head-to-head cardiovascular outcomes comparison.
5. Do They Have Different Side Effects?
The side effect profiles of semaglutide and dulaglutide are broadly similar, reflecting their shared mechanism. Both primarily affect the gastrointestinal system, particularly during the dose escalation period.
Common side effects shared by both
- Nausea (most common, typically mild to moderate and transient)
- Diarrhoea
- Vomiting
- Abdominal discomfort or bloating
- Decreased appetite (this is also a therapeutic effect)
In SUSTAIN 7, gastrointestinal adverse events were the most common reason for discontinuing treatment in both groups.
Importantly, adverse event rates were broadly similar across both drug arms, suggesting that semaglutide’s additional weight loss benefit does not come at the cost of a meaningfully worse side effect profile.
Rare but important risks (shared class effects)
- Pancreatitis: GLP-1 receptor agonists carry a labelled warning for pancreatitis. Both drugs should be discontinued if acute pancreatitis is suspected.
- Thyroid C-cell tumors: Observed in animal studies; patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not use either drug.
- Hypoglycaemia: Risk is low when used as monotherapy or with metformin, but may increase when combined with insulin or sulfonylureas.
Side Effect Comparison
| Side Effect | Semaglutide | Dulaglutide | Notes |
|---|---|---|---|
| Nausea | More common at higher doses | Common | Usually resolves within weeks |
| Vomiting | Common | Common | Reduce if persistent |
| Diarrhoea | Common | Common | Hydration important |
| Injection site reactions | Mild, infrequent | Mild, infrequent | Rotate injection sites |
| Discontinuation due to GI events | 4.5% (STEP 1) | Similar in SUSTAIN 7 | Slow titration helps |
| Pancreatitis | Rare (class warning) | Rare (class warning) | Discontinue if suspected |
6. What Is Their Availability in India Right Now?
The Indian availability landscape for these two medications has changed dramatically in 2026, particularly for semaglutide.
Semaglutide in India
Novo Nordisk’s Indian patent on semaglutide expired on 20 March 2026. Within days, major Indian pharmaceutical manufacturers launched their own DCGI-approved generic formulations.
Companies including Sun Pharma (Noveltreat, Sematrinity), Dr. Reddy’s (Obeda), Zydus Lifesciences, Mankind Pharma, Lupin, and Cipla, among others, are expected to launch over 50 brands across the year.
Branded Ozempic (for type 2 diabetes) and Wegovy (for weight management) remain available from Novo Nordisk. All versions, branded and generic, are Schedule H prescription-only medications and require a valid prescription from a registered medical practitioner.
Dulaglutide in India
Dulaglutide is available in India under the brand name Trulicity, manufactured by Eli Lilly. It is dispensed as a pre-filled single-dose pen in 0.75 mg and 1.5 mg strengths.
Trulicity is a prescription-only medication and is available through licensed pharmaceutical distributors and specialty pharmacies across major Indian cities.
Unlike semaglutide, dulaglutide’s Indian patent has not yet expired, meaning only the branded Eli Lilly product is currently available.
No DCGI-approved generic dulaglutide versions are available in the Indian market at this time.
India Availability Summary
| Feature | Semaglutide | Dulaglutide |
|---|---|---|
| Brand name(s) | Ozempic, Wegovy, Noveltreat, Obeda, Sematrinity + 40+ others | Trulicity |
| Manufacturer | Novo Nordisk (original) + major Indian generics (post-March 2026) | Eli Lilly |
| Patent status in India | Expired March 2026 — generics available | Patent active — branded only |
| Generic versions available? | Yes (40+ DCGI-approved generics) | No |
| Prescription required? | Yes — Schedule H | Yes — Schedule H |
| Available doses in India | 0.25 mg, 0.5 mg, 1.0 mg, 2.4 mg (pen) | 0.75 mg, 1.5 mg (pen) |
| Approved indication in India | Type 2 diabetes (Ozempic); weight management (Wegovy) | Type 2 diabetes |
7. Who Might Be a Better Candidate for Each Medication?
Neither medication is right for everyone. The decision depends on your specific health goals, your existing conditions, and what your physician recommends after evaluating your complete medical history.
Semaglutide may be considered when:
- Weight loss is a primary goal alongside glycaemic control. The Wegovy formulation at 2.4 mg is the only GLP-1 RA approved specifically for weight management.
- A wider dosing range is needed, given semaglutide’s approved doses go from 0.25 mg to 2.4 mg.
- An oral option is preferred. Rybelsus (oral semaglutide, 7 mg and 14 mg) is available for adults who prefer not to inject.
- The patient wants access to an affordable generic option, particularly now that DCGI-approved Indian generics have launched.
Dulaglutide may be considered when:
- Glycaemic control is the primary objective and weight loss is a secondary benefit.
- The patient has specific tolerability considerations. Some physicians may find dulaglutide’s side effect profile more predictable for certain patients during initiation, given its longer titration history in the Indian diabetes context.
- Children aged 10 years and older with type 2 diabetes. Dulaglutide has an approved paediatric indication; semaglutide currently does not.
Always have this conversation with a qualified endocrinologist or diabetologist. For patients seeking even greater weight loss potential beyond semaglutide, tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, is a newer option that has shown larger average weight reductions in clinical trials and is now available in India. For medically supervised GLP-1 treatment, explore the MetaGo weight loss program.
These decisions are highly individual, and the right choice depends on far more factors than a comparison article can capture.
| The Bottom LineBased on the best available head-to-head evidence from the SUSTAIN 7 trial, semaglutide produces significantly greater weight loss and HbA1c reduction than dulaglutide at comparable doses. Semaglutide 1.0 mg reduced body weight by 6.5 kg vs. 3.0 kg with dulaglutide 1.5 mg over 40 weeks.For patients whose primary goal is weight management, semaglutide at 2.4 mg (Wegovy/generic equivalents) is the only GLP-1 RA with a dedicated weight loss indication. Dulaglutide remains a well-studied, effective option for blood sugar control with meaningful cardiovascular benefits, particularly for type 2 diabetes management.Both medications require a doctor’s prescription and should be initiated, titrated, and monitored under medical supervision. Do not start, switch, or stop either medication without guidance from your treating physician. |
Frequently Asked Questions
Is semaglutide stronger than dulaglutide for weight loss?
Clinical evidence suggests yes. In the head-to-head SUSTAIN 7 trial, semaglutide produced approximately twice the body weight reduction of dulaglutide at comparable doses over 40 weeks.
Additionally, semaglutide at 2.4 mg (the Wegovy dose) has demonstrated mean weight loss of nearly 15% in obesity trials, a dose and indication that dulaglutide does not have.
Weight loss varies between individuals, so consult your physician for personalised expectations.
Can I switch from dulaglutide to semaglutide?
Switching between GLP-1 receptor agonists is possible and may be appropriate in some cases, but should always be done under medical supervision. For a detailed Ozempic vs Trulicity comparison, see our Ozempic vs Trulicity guide.
A physician will evaluate your current glycaemic control, tolerability of your current medication, and your health goals before recommending a change.
Do not switch medications without a consultation.
Which GLP-1 medication is available in India without a prescription?
Neither semaglutide nor dulaglutide is available without a prescription in India. Both are classified as Schedule H prescription-only medications.
While over-the-counter availability may occur informally, using these drugs without proper medical supervision is unsafe and potentially harmful.
What is the difference between Ozempic, Wegovy, and Rybelsus?
All three contain semaglutide, but they differ in formulation and indication. Ozempic is the injectable form approved for type 2 diabetes (doses up to 2.0 mg).
Wegovy is the higher-dose injectable form (2.4 mg) approved for chronic weight management. Rybelsus is the oral tablet formulation approved for type 2 diabetes.
Your physician will prescribe the formulation appropriate for your condition.
Are Indian generic versions of semaglutide as effective as Ozempic?
DCGI-approved generic semaglutide versions contain the same active molecule and must meet regulatory standards for bioequivalence.
From a pharmacological standpoint, the active ingredient is identical.
However, always obtain any prescription medication from a licensed pharmacy and ensure you have a valid prescription and physician oversight, regardless of the brand.
| Medical DisclaimerThis article is intended for informational purposes only and does not constitute medical advice. Semaglutide and dulaglutide are prescription medications that must be initiated, dosed, and monitored by a licensed healthcare professional. Do not start, stop, or modify any medication based on information in this article. Consult a qualified physician or endocrinologist before making any treatment decisions. |
